A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples